Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.33 |
| ▸ | SELL | P14151 | 1/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.32 |
| ▸ | MAG | P20916 | 4/20 | 0.31 |
| ▸ | CD22 | P20273 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311937 | 0.91 | NANP (0.40) | NANPL3MBTL1NEU3SELLSELP | |
| SCHEMBL15087688 | 0.86 | NANP (0.58) | NANPSELLSELPSIGLEC7MAG | |
| SCHEMBL13551450 | 0.85 | NANP (0.53) | NANPL3MBTL1NEU3SELLSELP | |
| SCHEMBL29311931 | 0.80 | L3MBTL1 (0.45) | NANPL3MBTL1NEU3SELLSELP | |
| SCHEMBL12302605 | 0.79 | L3MBTL1 (0.54) | NANPL3MBTL1NEU3 | |
| SCHEMBL15471527 | 0.79 | L3MBTL1 (0.54) | NANPL3MBTL1NEU3 | |
| SCHEMBL12015063 | 0.79 | L3MBTL1 (0.54) | NANPL3MBTL1NEU3 | |
| SCHEMBL16272856 | 0.79 | L3MBTL1 (0.54) | NANPL3MBTL1NEU3 | |
| SCHEMBL14648888 | 0.79 | L3MBTL1 (0.54) | NANPL3MBTL1NEU3 | |
| SCHEMBL12731860 | 0.79 | L3MBTL1 (0.54) | NANPL3MBTL1NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011628-B2 | Multivalent sialic acid derivatives | ADENOVIR PHARMA AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-20160207955-A1 | MULTIVALENT SIALIC ACID DERIVATIVES | ADENOVIR PHARMA AB (SE) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207955-A1 | MULTIVALENT SIALIC ACID DERIVATIVES | SIGLEC9, NEU3, NEU1 | NANP 239/4885L3MBTL1 2866/4885NEU3 2/4885 |
| US-10011628-B2 | Multivalent sialic acid derivatives | SIGLEC9, NEU3, NEU1 | NANP 239/4885L3MBTL1 2866/4885NEU3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.